203 related articles for article (PubMed ID: 12924544)
1. Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors.
Miller RF; Shahmonesh M; Hanna MG; Unwin RJ; Schapira AH; Weller IV
Antivir Ther; 2003 Jun; 8(3):253-7. PubMed ID: 12924544
[TBL] [Abstract][Full Text] [Related]
2. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.
Moyle G
Clin Ther; 2000 Aug; 22(8):911-36; discussion 898. PubMed ID: 10972629
[TBL] [Abstract][Full Text] [Related]
3. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial toxicity: myths and facts.
Moyle G
J HIV Ther; 2004 May; 9(2):45-7. PubMed ID: 15238876
[TBL] [Abstract][Full Text] [Related]
5. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms.
Nolan D; Mallal S
Antivir Ther; 2004 Dec; 9(6):849-63. PubMed ID: 15651744
[TBL] [Abstract][Full Text] [Related]
6. Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy.
Côté HC
Antivir Ther; 2005; 10 Suppl 2():M3-11. PubMed ID: 16152702
[TBL] [Abstract][Full Text] [Related]
7. A brief overview of mechanisms of mitochondrial toxicity from NRTIs.
Kohler JJ; Lewis W
Environ Mol Mutagen; 2007; 48(3-4):166-72. PubMed ID: 16758472
[TBL] [Abstract][Full Text] [Related]
8. HIV and mitochondrial toxicity in children.
Foster C; Lyall H
J Antimicrob Chemother; 2008 Jan; 61(1):8-12. PubMed ID: 17999978
[TBL] [Abstract][Full Text] [Related]
9. Long-term complications of nucleoside reverse transcriptase inhibitor therapy.
Dieterich DT
AIDS Read; 2003 Apr; 13(4):176-84, 187. PubMed ID: 12741368
[TBL] [Abstract][Full Text] [Related]
10. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
Nolan D; Hammond E; James I; McKinnon E; Mallal S
Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.
Kakuda TN
Clin Ther; 2000 Jun; 22(6):685-708. PubMed ID: 10929917
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside analogues and mitochondrial toxicity.
Fleischer R; Boxwell D; Sherman KE
Clin Infect Dis; 2004 Apr; 38(8):e79-80. PubMed ID: 15095236
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients.
Maagaard A; Holberg-Petersen M; Kollberg G; Oldfors A; Sandvik L; Bruun JN
Antivir Ther; 2006; 11(5):601-8. PubMed ID: 16964828
[TBL] [Abstract][Full Text] [Related]
14. [Lactic acidosis and hepatic mitochondrial changes during a treatment with zidovudine].
Charton-Bain MC; Flamant M; Aubertin JM; Belair MF; Gilquin J; Kazatchkine M; Bruneval P
Gastroenterol Clin Biol; 1997; 21(12):979-81. PubMed ID: 9587562
[TBL] [Abstract][Full Text] [Related]
15. [Impact of reverse transcriptase inhibitors on sperm mitochondrial and genomic DNA in assisted reproduction techniques].
Sergerie M; Martinet S; Kiffer N; Teulé R; Pasquier C; Bujan L
Gynecol Obstet Fertil; 2004 Oct; 32(10):841-9. PubMed ID: 15501159
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial dysfunction in HIV infection: an overview of pathogenesis.
Rustin P
J HIV Ther; 2001 Mar; 6(1):4-12. PubMed ID: 11501198
[No Abstract] [Full Text] [Related]
17. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.
Maagaard A; Holberg-Petersen M; Løvgården G; Holm M; Pettersen FO; Kvale D
J Infect Dis; 2008 Nov; 198(10):1474-81. PubMed ID: 18851688
[TBL] [Abstract][Full Text] [Related]
18. Effect of the substitution of one nucleoside analogue by one non-nucleoside reverse transcriptase inhibitor over mitochondrial DNA levels.
De Felipe B; Blanco A; Soriano-Sarabia N; Muñoz-Fernández MA; Genebat M; Vallejo A; Leal M
Infection; 2008 Jun; 36(3):266-70. PubMed ID: 18463785
[TBL] [Abstract][Full Text] [Related]
19. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
Côté HC; Magil AB; Harris M; Scarth BJ; Gadawski I; Wang N; Yu E; Yip B; Zalunardo N; Werb R; Hogg R; Harrigan PR; Montaner JS
Antivir Ther; 2006; 11(1):79-86. PubMed ID: 16518963
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside analogues toxicities related to mitochondrial dysfunction: focus on HIV-infected children.
Viganò A; Giacomet V
Antivir Ther; 2005; 10 Suppl 2():M53-64. PubMed ID: 16152706
[No Abstract] [Full Text] [Related]
[Next] [New Search]